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ABSTRACT 
 With all the technology available to us, the causes of cancers are still 
puzzling researchers all over the world.  Everyday different approaches are being 
tested to help cure various cancers.  With the development of molecular biology, we 
are able to understand cancer more at molecular level, which helps us look at 
different methods to treat cancer patients.  
 The molecular basis for leukemia cancers are understood to a level where we 
are able to design treatments that specifically target proteins responsible for the 
disease.  One of those proteins is the Bcr-Abl tyrosine kinase which is mostly 
responsible for chronic myelogenous leukemia.  PD173955 is a drug that is capable 
of inhibiting Bcr-Abl tyrosine kinase more potently than any other chemotherapeutic 
drug reported drug.  The problem with PD173955 and a very large number of other 
drugs is their limited solubility in aqueous environments which makes them less 
desirable for medical applications. 
 Aptamers are newly developed reagents and their utilization in medicinal 
applications is so far very limited.  However their characteristics make them perfect 
tools to help solve problems associated with PD173955.  Here we report a 
successful selection of the RNA aptamer that is capable of binding PD173955 with a 
dissociation constant of 1-2 µM using SELEX.  The data obtained with selected 
aptamer suggests that the aptamer could be used to protect PD173955 from 
aqueous environment.  The selection process of the RNA aptamer will be described 
in detail.  The selected aptamer has been reduced to its minimal binding domain 
without loss of affinity.   
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 CHAPTER 1: INTRODUCTION TO LEUKEMIA AND PROBLEMS ASSOCIATED 
WITH CURRENT TREATMENTS 
 
INTRODUCTION 
Leukemia  
Leukemia is a type of cancer that affects cells in the blood and bone marrow, 
and results in overproduction of white blood cells.  These abnormal cells are not 
capable of developing further and accumulate over time to displace normal blood 
cells.  Based on how quickly leukemia advances, it is characterized into two types, 
chronic and acute.  Chronic type leukemia progresses very slowly.  An acute type of 
leukemia is more aggressive and progresses much faster.  In addition to these two 
classifications, leukemia is also classified by the types of white blood cells that it 
influences.   
There are four categories of leukemia. Chronic myeloid leukemia (chronic 
myelogenous leukemia, CML), accounts for about 4,600 new cases and 490 deaths 
in the U.S. each year. (Society 2007)  It influences mainly adults.  Chronic 
lymphocytic leukemia (chronic lymphoblastic leukemia, CLL), accounts for about 
9,700 new cases in the U.S. each year. (Society 2007)  Mostly it influences patients 
55 or older.  Acute myeloid leukemia (acute myelogenous leukemia, AML) accounts 
for about 11,900 new cases each year in the U.S. (Society 2007)  It influences both 
adults and children.  Acute lymphoblastic leukemia (acute lymphoblastic leukemia, 
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ALL)  accounts for 4,000 new cases in the U.S. each year (Society 2007).  It mostly 
influences children, but can influence adults. 
CML affects the developmental pathway of white blood cells, called 
granulocytes, in the blood and bone marrow.  Some of these cells never become 
mature white blood cells, and are called blasts.  Over time, in people with CML 
granulocytes and blasts take over the blood cell population and displace red blood 
cells and platelets.   
Depending on the number of blasts and granulocytes, there are three phases 
of leukemia.  In the chronic phase, which is characterized as a slowly progressing 
disease, patients may have no leukemic symptoms.  Most of the white blood cells 
are mature cells in the blood and bone marrow.  The chronic phase can last from 
several months to several years, averaging about five years.  In the accelerated 
phase of CML patients show symptoms of leukemia, which include fever, poor 
appetite, and weight loss.  There are some immature white blood cells present in 
blood and bone marrow (between 5 to 30 percent) (Talpaz, Silver et al. 2002).  In the 
blast crisis phase there are more then 30 percent immature white blood cells present 
in blood and bone marrow.  Symptoms such as anemia and recurring infections are 
typical.  Generally patients in the blast crisis phase of CML die within 6-12 months 
after being classified in this phase  (Kurzrock, Kantarjian et al. 2003).  The facts and 
statistics cited above regarding the nature of the leukemia and its statistics were 
obtained from http://www.leukemia-lymphoma.org/, and http://www.cancer.gov/, an 
official webpage of United States National Cancer Institute. 
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CML accounts for 20 percent of newly diagnosed leukemia cases in adults.  If 
left untreated 20-30 percent of CML patients die within two years, and 25 percent die 
each subsequent year. 
The causes of leukemia are still puzzling scientists and physicians, but 
studies identified certain factors that can contribute to development of the disease.  
For example, people who are exposed to high levels of radiation have a higher risk 
of developing leukemia then others.  Such high levels of radiation are caused by 
atomic bombs or nuclear power plant accidents (such as Chernobyl in 1986).  
Medical treatments that use high levels of radiation to treat cancers, can be linked to 
the development of radiation-induced leukemia (Shuryak, Sachs et al. 2006).  There 
is strong clinical and epidemiological evidence that ionizing radiation can cause 
leukemia by creating DNA damage.  When hematopoietic cell lines were exposed to 
high levels of γ-irradiation, the formation of the fusion genes characterized in 
leukemia was observed (Deininger, Bose et al. 1998) 
People who are exposed to certain chemicals such as benzene or 
formaldehyde may also be at greater risk of leukemia.  It has been demonstrated 
that benzene can cause gene duplicating mutations in human bone marrow.  Gene 
translocation in peripheral blood cells, and chromosome-specific aneuploidy can 
also be linked to leukemia (Smith 1996).  Studies of 26000 industrial workers who 
were exposed to formaldehyde concluded that formaldehyde may cause leukemia in 
humans (Hauptmann, Lubin et al. 2003). 
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Another cause of leukemia is chemotherapy that uses alkylating agents.  
Children who were treated for cancer using alkylating agents have a 4% higher 
chance to develop leukemia twenty years after cancer treatment than the ones who 
went through radiation therapy (Tucker, Meadows et al. 1987). 
Down’s syndrome and some other genetic diseases caused by abnormal 
chromosomes can also increase the risk of leukemia.  Patients with Down’s 
syndrome have a 10-20 fold higher risk of developing leukemia compared to the 
general population (Fong and Brodeur 1987).  Most people who have these risk 
factors do not develop leukemia and many people who develop leukemia have none 
of the risk factors. 
 
The Philadelphia chromosome 
About 90% of CML patients have a gene mutation called the Philadelphia 
chromosome (John 2003; Kurzrock, Kantarjian et al. 2003).  The Philadelphia 
chromosome results from translocation of the Abelson gene from chromosome 9 to 
the breakpoint cluster region (Bcr) on chromosome 22 (John 2003) (Figure 1a, 
Page 5).  The position where translocation occurs within the Bcr gene varies, 
therefore a number of different size proteins are translated from RNA transcripts 
produced from different translocated chromosomes.  Therefore, the Bcr-Abl proteins 
are sized at 190, 210, and 230 kDa (Kurzrock, Kantarjian et al. 2003).  The 
 Philadelphia chromosome is 
from parent to child. 
 
Figure 1: The Philadelphia Chromosome, Gleevec, and PD173955.
translocation of the Abl gene from chromosome 9 to 
fused chromosome is called Philadelphia Chromosome, (b) the structure of Gleevec, and (c) 
the structure of PD173955. 
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sufficient to initiate the disease.  In later stages of leukemia it has been shown that 
mutations within this translocation are the reason for the multi drug resistance 
(MDR). 
 
Abl protein kinase 
 The Abl protein kinase expressed by humans is 145 kDa (Kurzrock, 
Kantarjian et al. 2003).  The N-terminal half of  Abl (60 KDa) is homologous to the 
Src family of tyrosine kinases (Van Etten 1999; Nagar, Hantschel et al. 2003).  It 
contains SH2 and SH3 domains and the tyrosine kinase domain.  The SH2 and SH3 
domains mediate protein-protein interactions and are involved in signal transduction.  
The Abl protein kinase is a nonreceptor tyrosine kinase.  Several functional domains 
have been identified in Abl.  The C-terminal domain includes a nuclear localization 
signal, DNA binding domain, and actin binding domain.  Normal Abl phosphorylation 
is tightly regulated by the N-terminus through auto-inhibition and loss of this region 
through fusion creates unregulated kinase activity.  The mechanism of regulation is 
not fully understood (Nagar, Hantschel et al. 2003). 
 
Bcr protein kinase and Bcr-Abl fusion protein kinase 
 The Bcr gene is located on the long arm of chromosome 22, and is translated 
into two major proteins that have molecular weights of 130 kDa and 160 kDa.  They 
are located in both the nucleus and cytoplasm.  Like c-Abl the Bcr protein has 
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multiple domains that are involved in multiple functions.  Two domains on the C-
terminal half of Bcr are involved in two major signaling pathways in eukaryotes 
(phosphorylation and guanosine triphosphate binding) (Kurzrock, Kantarjian et al. 
2003).  The two domains that are involved in activation of c-Abl have been identified.  
Domain 1, which consists of the amino acids 1-63, is responsible for activating the 
tyrosine kinase activity.  The amino acids 176-242 are capable of binding to the SH2 
domain of Abl in vitro (McWhirter, Galasso et al. 1993). 
Depending on the location of the Bcr gene fusion, two fusion proteins are 
translated with very similar activities: p210Bcr-Abl and p190Bcr-Abl (Kurzrock, Kantarjian 
et al. 2003).  The p190Bcr-Abl variant has higher tyrosine kinase activity and is 
associated with the more aggressive form of the disease (Lugo, Pendergast et al. 
1990).   
Both forms of the Bcr-Abl protein kinases interact with activators of the Ras 
signaling pathway through binding to the SH2 domains of Grb2, Scr, and Shc.  They 
also interact with intracellular substrates to cause cytoskeletal structural deformity.  
In addition, they interact with modulating proteins such as Bcl-2 or Bad, that are 
involved in suppression of cell death and apoptosis.  Expression of the Bcr-Abl 
fusion proteins affect the DNA damage response process that is involved in DNA 
repair (Kurzrock, Kantarjian et al. 2003). 
In summary the Bcr-Abl fusion gene produces a deregulated Bcr-Abl tyrosine 
kinase, which is the molecular basis of CML.  Bcr-Abl is capable of auto-
phosphorylating itself, inducing cells to proliferate and causing cancerous cells to 
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suppress apoptosis, which causes a large number of stems cells to develop into 
granulocytes and blast cells.   
 
CURRENT TREATMENT  
Tyrosine Kinase Inhibitor (Gleevec) 
In 2001, the FDA approved a new revolutionary drug, a tyrosine kinase 
inhibitor called Imatinib mesylate or “Gleevec” (also known as STI571 and 
CGP57148B) (Figure 1b, Page 5) (Kurzrock, Kantarjian et al. 2003).  Early results 
showed high efficacy of Gleevec and low toxicity which made Gleevec very attractive 
for treatment of CML patients.  Gleevec is used to treat CML patients in all three 
phases, and is also prescribed for patients who have gastrointestinal kit-derived 
stromal tumors.  It is a member of the 2-phenylaminopyrimidine class of compounds 
that was developed by Ciba-Geigy (now Novartis Pharmaceuticals) (Nagar, 
Bornmann et al. 2002; Goldman 2004).  In addition to inhibition of the Abl tyrosine 
kinase, this drug potently inhibits other tyrosine protein kinases: the Kit (receptor for 
stem cell factor), the platelet-derived growth factor receptor (PDFGR-A and B), the 
Abelson related gene (ARG), and possibly other unidentified kinases (Goldman 
2004).  
The fusion of Bcr to Abl causes the Bcr-Abl tyrosine kinase to be almost 
always in the active conformation, but the tyrosine kinase dynamically cycles 
between inactive and active conformations.  Crystallographic studies have shown 
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that Gleevec binds to the ATP binding site on the unphosphorylated, inactive 
conformation of the Abl kinase (Nagar, Bornmann et al. 2002).  This suggests that 
binding of Gleevec might lock Bcr-Abl tyrosine kinase in its inactive form.  Another 
mode of Gleevec inhibition is to bind newly synthesized Bcr-Abl tyrosine kinase.  
Initial treatment of CML patients with Gleevec showed extraordinary results, 
because it destroyed 90 percent of cancerous cells in the chronic phase. 
 
Problems with Gleevec 
Increased resistance to Gleevec and therapy failures are observed in patients 
with advanced CML.  Because Gleevec is only effective against the inactive Bcr-Abl 
tyrosine kinase, it has been shown that it is much less efficient in patients who are in 
the blast crisis phase of CML (Druker, Sawyers et al. 2001).   
 Studies using Bcr/Abl+ cell lines resistant to Gleevec showed that acquired 
resistance can be associated with increased expression of the Bcr-Abl protein, which 
is usually due to gene amplification (le Coutre, Tassi et al. 2000; Weisberg and 
Griffin 2000; Gorre, Mohammed et al. 2001).  There are also cases where resistance 
to Gleevec occurred in cell lines or patients who were not previously exposed to 
Gleevec.  When human leukocytic cells (LAMA84) were incubated with increasing 
concentrations of Gleevec for six months, they showed a 10 fold higher IC50 for 
Gleevec,  increased concentration of Bcr-Abl, and higher Bcr-Abl mRNA levels than 
parental sensitive cell lines,.  These more resistant cell lines showed 14 copies of 
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the fused Bcr-Abl gene per cell compared to the 4 copies that were present in the 
parent cells. 
 Because Gleevec binds to the ATP binding site on the Abl kinase domain, 
acquired resistance to Gleevec led researchers to look for possible mutations in the 
ATP binding pocket that prevented binding of Gleevec, while permitting binding of 
ATP.  One group reported mutations in 17 different residues in the kinase domain 
(Branford, Rudzki et al. 2003).  Another group discovered that a single amino acid 
substitution in a threonine residue of the Abl kinase domain, known to form a critical 
hydrogen bond with the drug, is sufficient to prevent Gleevec binding to the kinase 
domain (Gorre, Mohammed et al. 2001). 
The biological availability of Gleevec is reduced by the over expressed alpha-
1 acid glycoprotein (AGP) in CML cancer cell lines.  AGP  binds Gleevec and blocks 
its diffusion from the blood to cancerous cells (Gambacorti-Passerini, Barni et al. 
2000; Hamada, Miyano et al. 2003). 
 
Other types of treatments 
Desatinib, also known as BMS-354825, is another tyrosine kinase inhibitor 
that is prescribed to patients who are in the later stages of the CML (Talpaz, Shah et 
al. 2006).  This drug is only prescribed to patients who did not respond to Gleevec or 
can not use it for another reason.  Currently this drug is being tested to be used to 
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treat patients in the initial stages of CML, to improve treatment of CML patients by 
avoiding problems associated with Gleevec resistant CML patients. 
Chemotherapeutic drugs are used to treat CML patients by either killing the 
cancer cells or stopping them from dividing. They can be taken by mouth, injected 
into veins, or injected into the organ that needs to be treated.  The pathway by which 
the drug is delivered to the CML patient depends on the stage of CML.  Damage to 
healthy cells is commonly observed with the use of chemotherapeutic drugs, which 
lowers the patients’ immune system, increases bleeding and a loss of energy.  Some 
chemotherapy drugs may affect cancer patients’ fertility.  Women’s menstrual cycles 
may occur irregularly and stop and men may stop producing sperm.  Some of these 
side effects become permanent.   
Biological therapy is a treatment that uses the patient’s immune system to 
fight cancerous cells.  Interferons are proteins that are produced by the body to fight 
foreign cells.  They can be give intravenously, intramuscularly, or subcutaneously to 
patients.  Flu-like symptoms are observed with each interferon administration.  
Depression and suicide have been reported with patients who use interferons.  
Another way to treat patients with CML is with a combination of high dose 
chemotherapy and stem cell transplantation.  In this treatment regiment high doses 
of chemotherapeutic drugs are given to the patients and their damaged blood cells 
are replaced with immature donor blood cells.   
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Donor lymphocyte infusion is a treatment in which donor lymphocytes are 
injected through one or multiple infusions into the patients.  Infused lymphocytes 
recognize the patient’s cancer cells as foreign then attack and kill them.  Donor 
lymphocyte treatment has all the side effects associated with chemotherapy and 
radiation.  
The last option available to CML patients is splenectomy where the patient’s 
spleen is surgically removed.  This treatment is performed after all the above 
treatments are unsuccessful.  Splenectomy is more effective in patients who have 
CLL, and has little effect with patients who are diagnosed with CML.  Studies with 
patients who went through splenectomy in early CML show no increase in survival 
rate.  Splenectomy may benefit CML patients in more advanced phases of leukemia, 
and patients who underwent bone marrow transplantation (Mesa, Elliott et al. 2000).  
 
PROPOSED TREATMENT 
Due to the resistance problems that occur in patients who are treated with 
Gleevec, combined with the dangerous side effects associated with other 
treatments, it is necessary to develop an effective method to treat CML.  From the 
search for a more effective drug, a new class of compounds emerged as a possible 
solution to problems associated with current treatments.  The pyrido[2,3-
d]pyrimidines constitute a large group of compounds that were developed to target 
different tyrosine kinases.  These compounds were initially developed as broadly 
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active inhibitors of several tyrosine kinase such as Src, platelet-derived growth factor 
receptor and fibroblast growth factor receptor (FGFR) (Wissing, Godl et al. 2004).  
PD173955 is a pyrido[2,3-d]pyrimidine that was shown to potently inhibit the Bcr-Abl 
and c-kit tyrosine kinases in vivo (Wisniewski, Lambek et al. 2002; Wissing, Godl et 
al. 2004) (Figure 1c, Page 5).  PD173955 is capable of inhibiting the kinase activity 
of Bcr-Abl with an IC50 of 1-2 nM in vitro.  Crystallographic studies show that 
PD173955 can recognize multiple Bcr-Abl kinase conformations, which could explain 
its higher efficacy as an inhibitor (Nagar, Bornmann et al. 2002).  PD173955 binds 
Bcr-Abl tyrosine kinase in its active and inactive conformations and is very efficient 
against most Gleevec resistant CML cell lines.  
PD173955 also binds other kinases, such as p38, GAK, and RICK (Wissing, 
Godl et al. 2004) but with lower affinity compared to Src and Abl kinases.  Other 
kinases such as Mek1, Jnk2, and Aurora A required 1,000-10,000 higher 
concentration of PD173955 derivative to achieve half of the maximum inhibition.  
The same group reported the IC50 for Abl and Scr kinases in the subnanomolar 
range by PD173955 derivative, which is about 30 fold less then previously reported 
by others.  They suggest that possible reason for the discrepancy is the amount of 
enzyme used in their assays compared to others. 
PD173955 has a significant antiproliferative activity due to a potent arrest of 
mitotic progression through inhibition of the Src family of tyrosine kinases (Moasser, 
Srethapakdi et al. 1999).  This effect was observed in cancer cell lines of all types 
including breast cancer cell lines, prostate cancer, ovarian cancer, colon cancer, 
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lung cancer, epidermal cancer, as well as non-transformed cell lines: MCF-10A and 
NIH-3T3.  In MDA-MB-468 breast cell lines PD173955 inhibits Src and Yes kinase 
activities (Moasser, Srethapakdi et al. 1999).   
A major concern for the pyrido[2,3-d]pyrimidines is their broad specificity for 
other protein kinases (Wissing, Godl et al. 2004).  But the broad specificity of 
compounds such as PD173955 can be used to attack leukemic cells at different 
cellular targets by inhibition of several tyrosine kinases involved in the cell 
proliferation.  In addition, there are data from medicinal chemistry studies showing 
that the specificity of pyrido[2,3-d]pyrimidine based compounds can be efficiently 
improved (Wissing, Godl et al. 2004).  For example, by replacing the 6-(2,6-
dichlorophenyl) moiety with a 6-(3',5'-dimethoxyphenyl) produced a highly selective 
FGFR tyrosine kinase inhibitor (Hamby, Connolly et al. 1997).   
 There is not much known of the pharmacokinetic properties of the pyrido[2,3-
d]pyrimidines.  This is mostly due to their limited solubility, and the inconsistent 
dose-dependent responses observed in mouse xenografts (Wissing, Godl et al. 
2004).  The limited solubility is the major problem associated with the pyrido[2,3-
d]pyrimidines and therefore not too much research has been performed to improve 
their specificity.  The limited solubility of PD173955 in aqueous environments was 
confirmed by a researcher in our lab (Marjan Mokhtarian).  The maximum solubility 
of PD173955N in 5% DMSO was 35 µM.  Although PD173955 is potent inhibitor of 
Bcr-Abl, its limited solubility in water makes it undesirable as a drug.  This is a 
reason, why the benefits of these compounds are not explored further.  Use of 
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compounds like PD173955N in binding assays in vitro is very challenging task, 
because it is very difficult to reach high enough concentrations necessary for these 
assays.   
 
The use of aptamer technology may improve efficiency of pyrido[2,3-
d]pyrimidines 
Improved PD173955 solubility and targeting can be addressed by the use of 
carrier molecules that decrease exposure of the hydrophobic molecules to the 
aqueous environment and target the appropriate receptors.  Nucleic acid aptamers 
provide a means for developing drug carriers.  Aptamers are single stranded RNA or 
DNA sequences that bind their targets with high specificity and affinity (picomoles to 
micromoles).  Since their first introduction in the 1990s there have been a few 
hundred aptamers selected to various targets.  These targets include small 
molecules, amino acids, peptides, and proteins (Proske, Blank et al. 2005).  Most 
aptamers are obtained using a technique called SELEX “Systematic Evolution of 
Ligands by EXponential enrichment”.  Using this method it is possible to select rare 
nucleic acids with the desired characteristics from a very large number of nucleic 
acid sequences.  The technique was developed by two groups in 1990.  One group 
selected an aptamer that recognizes the T4 bacteriophage DNA Polymerase (Tuerk 
and Gold 1990), and the other group selected an aptamer that binds organic dyes 
(Ellington and Szostak 1990).   
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Aptamers are generally 15-40 nucleotides long and can be composed of a 
chemically modified backbone (2’-fluoro or 2’-O-methyl), which increases their 
half-lives in vivo from hours to days.  They can be chemically synthesized using 
standard nucleic acid synthesis methods, which makes them attractive therapeutic 
agents.  Aptamers are selected from a pool of nucleic acids (1012-1015 molecules), 
containing oligonucleotides each with a different sequence.  These oligonucleotides 
within the pool provide a number of three-dimensional conformations from which to 
select aptamers, making them ideal tools to select rare well-defined conformations to 
bind their targets tightly. 
 
Aptamer functions in vivo  
Aptamers selected in vitro have very similar functions when tested in vivo.  
For example, when an RNA aptamer to the nucleocapsid protein of the human 
immunodeficiency virus-1 was expressed in cells as a intracellular RNA aptamer 
“intramer”, it inhibited packaging of the viral genomic RNA (Kim and Jeong 2004).  
The same aptamer completely abolished nucleocapsid binding to the stable 
transactivation response hairpin and psi RNA stem-loops of HIV-1 RNA (Kim and 
Jeong 2004). 
Another aptamer, that was shown to be functional inside a multicellular 
organism, is a anti B52 protein aptamer (Shi, Hoffman et al. 1999).  B52 is a 
member of the Drosophila SR protein family, which is responsible for mRNA splicing.  
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Previous work showed that B52 is essential for Drosophila life.  Deletion and over-
expression of B52 results in death or causes critical morphological deformation of 
the organism (Ring and Lis 1994).  Shi et al. (Shi, Hoffman et al. 1999) generated a 
Drosophila that both over-expressed B52 and expressed an aptamer that recognized 
B52.  They used the generated Drosophila to demonstrate efficacy of the aptamer in 
vivo.  Reversal of the morphological deformation that was associated with B52 
expression was observed due to anti-B52 suppression by the aptamer. 
PDGF-B is involved in the regulation of interstitial fluid pressure (IFP).  
Elevated IFP is a property of solid tumors (an abnormal mass of tissue that does not 
contain fluid or cysts) that prevents delivery of chemotherapeutic drugs.  The IFP 
can be also associated with increased tumor size, malignancy and poor prognosis in 
cancer patients.  Blocking PDGF-B in KAT-4 thyroid carcinoma tumors with the 
tyrosine kinase inhibitor Gleevec dramatically decreased the tumor IFP in vivo and 
increased uptake of the chemotherapeutic drug Taxol. 
The ability to chemically stabilize aptamers against nuclease degradation 
through 2’-O-methyl modification of the purine nucleotides, and attaching them to 
higher molecular weight polyethylene glycol (PEG) makes them good tools for 
extracellular drug delivery.  One group selected an aptamer that blocks PDGF-B 
binding to its receptor with a dissociation constant in the nanomolar range (Kd ~100 
nM) and attached it to PEG (Green, Jellinek et al. 1996).  Treatment of KAT-4 
xenograft mice with the PEG-conjugated PDGF-B aptamer decreased IFP in vivo 
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and increased uptake of Taxol (Pietras, Rubin et al. 2002).  Here we can see the 
advantage of using an aptamer over a tyrosine kinase inhibitor like Gleevec.   
Aptamers are newly developed reagents and their utilization in the clinical 
applications is so far very limited.  But one aptamer is already approved for clinical 
use and a number of other aptamers are in the process of development for medical 
use.  They are being developed for topical and intravenous applications in the clinic.  
The first FDA-approved aptamer is the polyethylene glycol linked anti-VEGF 
aptamer, NX1838 also known as Macugen, which is used to cure AMG “age related 
macular degeneration” and diabetic retinopathy (Pendergrast, Marsh et al. 2005; Ng, 
Shima et al. 2006).  Vascular endothelial growth factor (VEGF) is responsible for 
blood vessel leakage and their advanced expansion towards the retina of the eye.  
The abnormal vessels leak fluid, blood, and lipids, which damage the photoreceptors 
of the eye. If left untreated 45 percent of these unhealthy eyes will develop moderate 
vision loss and 22 percent will develop severe vision loss.  Macugen blocks VEGF’s 
actions, which prevents the symptoms associated with VEGF’s actions from 
occurring.  With a single ocular injection of Macugen, 80 percent of AMD patients 
had improved or stabilized vision after three months.  All patients who continued to 
receive the ocular injections showed improved vision compared to the patients who 
didn’t receive the injections (Pendergrast, Marsh et al. 2005). 
Another aptamer that is under development for medical use is a thrombin 
inhibitor, a drug called ARC183.  It is being developed by Archemix for potential use 
as an anticoagulant in coronary artery bypass graft (CABG) surgery. The only FDA 
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approved drug to currently serve as an anticoagulant is heparin.  The advantages of 
heparin include a low cost of synthesis, and the fast reversal of the heparin side 
effects by protamine.  The serious side effects associated with the use of 
heparin/protamine include bleeding and platelet count reduction.  There is a strong 
need for a new low cost drug.  ARC183 is a strong anticoagulant in vitro, and inhibits 
thrombin-catalyzed activation of fibrinogen, and thrombin-induced platelet 
aggregation in cynomolgus Macaques (Macaca fascicularis) (Griffin, Tidmarsh et al. 
1993). 
An example where an aptamer can be used to suppress mesangial cell 
proliferation is a PDGF-B (ARC127) binding aptamer in rats.  Certain residues of 
ARC127 aptamer have been modified with 2-O-methyl moieties to increase its 
stability in vivo without loss of aptamer affinity.  ARC127 is being considered for 
medical applications where PDGF-B has been implicated.  The target diseases 
include: glomerulonephritis, pulmonary hypertension, and intimal hyperplasia 
following percutaneous transluminal angioplasty (Floege, Ostendorf et al. 1999; 
Vaish, Larralde et al. 2003). 
In the past two decades multiple nanoparticle carriers have been developed 
to deliver highly hydrophobic drugs to their targets (Liangfang Zhang 2007).  
Liposomes and cationic core shell nanoparticles have been used to deliver drugs 
and DNA plasmids to cells.  The surface of the nanoparticles can be coated with 
aptamers so they would deliver drugs to specific targets.  One research group 
developed a system where they were able to deliver hydrophobic and hydrophilic 
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chemotherapeutic drugs to prostate cancer cells intracellularly using aptamer coated 
nanoparticles (Liangfang Zhang 2007).  Prostate specific membrane antigen (PSMA) 
is expressed on the surface of prostate cancer cells.  This group used an aptamer 
that binds PSMA and attached it to a nanoparticle to deliver chemotherapeutic 
drugs.  The aptamer was preloaded with the intercalating hydrophilic drug and the 
nanoparticle also contained the hydrophobic chemotherapeutic drug.  The uptake of 
chemotherapeutic drugs by prostate adenocarcinoma cells was modeled using the 
hydrophobic and the hydrophilic dyes and was visualized with cells that express 
PSMA using fluorescence microscopy.  They reported no drug uptake by cancer 
cells that do not express PSMA compared to cells that express PSMA.  This is an 
example of targeted drug delivery that can be achieved with aptamers. 
All examples discussed here show how aptamer technology has advanced 
since aptamer introduction in 1990.  Aptamers can be used for a number of different 
applications.  The aptamers’ properties and functions are compared to monoclonal 
antibodies, but they differ from antibodies in many ways.  Unlike for antibodies, the 
production of aptamers can be done in vitro without the use of animals or cell lines, 
and aptamers can be selected to almost any target including toxic ones.  Aptamers 
are chemically produced, allowing the attachment of a number of different reporter 
molecules or other molecules in precise locations on the aptamer (Davis, Lin et al. 
1998).  They are stable under a wide range of buffer conditions, and can be 
denatured and renatured without any loss of affinity, making them easily stored.  The 
whole SELEX process required to select an aptamer can be done in 6-8 weeks.  
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Unlike for antibodies, the aptamers can be reselected to increase their affinity or 
further modified to change their specificity.  When compared to the antibody the 
design and production of aptamers is very inexpensive.  These are the 
characteristics that make aptamers more attractive then antibodies.   
The SELEX process is very simple and can be done on the bench top or by 
automated systems in a short period of time (Cox, Hayhurst et al. 2002; Eulberg, 
Buchner et al. 2005).  The basic procedure involves a number of iterative rounds 
that consist of binding, partitioning, and amplifying the desired nucleic acid from a 
combinatorial pool that consists of up to 1016 different sequences.  Even though the 
basic procedure is very simple, even small alterations can produce unwanted results 
(Murphy, Fuller et al. 2003).  One has a number of different decisions to make 
before performing SELEX.  Some of the decisions which seem to be most critical for 
successful SELEX include the initial binding conditions, the separation method, and 
the elution method.  The first selection processes were performed by attaching the 
target to a solid support and passing the selection pool through it (Tuerk and Gold 
1990).  Depending on the size of the target more recent selection procedures do not 
use target attached to the solid support, but perform the binding reaction step in 
solution.  The target nucleic acid complex can be captured by the use of a solid 
support like the agarose beads or by nitrocellulose membranes if the target is large 
enough.  For smaller targets attachment to a solid support is unavoidable at this 
time.  Dissociation of the bound nucleic acids from the target can be done by 
passing a high concentration of target through the column or the filter.  If the target 
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molecule is scarce or insoluble at high concentrations, denaturing reagents such as 
concentrated urea can be use to elute the aptamer pool from the target.  These 
methods consume target concentrations in the range of 1-100 mM and 
oligonucleotides pools concentrations in the range of 0.001 to 1 mM.  Once the 
desired characteristics of the selected aptamer population are achieved, the 
constituents of the remaining population are cloned and the cloned oligonucleotides 
sequenced.  After the aptamer candidate with the lowest dissociation constant is 
chosen, the size of the aptamer is reduced to a minimum binding region.  Usually 
optimization leads to increased binding affinity and specificity of the aptamer due to 
a decrease in a number of competing and nonbinding conformations (Pendergrast, 
Marsh et al. 2005). 
 SELEX is best applied when used to generate aptamers against large 
molecules, because they offer larger surface areas for the aptamer target interaction 
(Hamula, Guthrie et al. 2006).  Target molecules must be stable, and easily 
captured.  Proteins make ideal aptamer targets and that is why there are so many 
aptamers generated against them.  The SELEX procedure to small molecules has 
not been as successful as to larger molecules (Hamula, Guthrie et al. 2006).  This is 
mostly due to the small surface area that the nucleic acids can bind.  Aptamers 
generated against small molecules have KDs in that range from low µM to mM, 
compared to those of larger targets that are in picomolar to the mid nanomolar 
range.   
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For this study PD173955 was chosen as an aptamer target because of its 
great potential for inhibition of the Bcr-Abl tyrosine kinase.  Also this compound was 
chosen due to its low solubility.   PD173955 represents many potent compounds 
with low solubilities produced by the chemical companies.  We intend to use 
aptamer technology to overcome the problems associated with PD173955.  If 
successful, this approach could be applied and be used with other members of the 
pyrido[2,3-d]pyrimidines class of compounds and with other drugs. 
Aptamers can be used as carriers to encapsulate hydrophobic compounds 
like PD173955 to protect them from aqueous environments in which they have low 
solubility.  The problems associated with these types of compounds before they can 
be used for medial applications are low solubility resulting in low concentrations 
inside the cell.  The advantage of using aptamers to solve this problem is because 
the complexity of the random oligonucleotides in the starting original pool can take 
numerous tertiary conformations and can bind to almost any target. Aptamers often 
completely wrap around their targets upon binding. This characteristic of an aptamer 
can be used to increase the concentration of the compounds inside of the cell.  A 
novel and efficient model to help protect insoluble compounds like PD173955 from 
aqueous environments and to increase its concentration inside of the cancerous 
cells would be very beneficial.  The first step is to select an aptamer that is capable 
of recognizing and binding PD173955.  PD173955 has very limited solubility in 
aqueous environment.  Even though the original pool contains a large number of 
different tertiary structures of oligonucleotides, selecting the one that can bind a 
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target with as low a solubility as PD173955 was a very challenging task.  The affinity 
of the selected RNA for PD173955N is much lower than affinity of Bcr-Abl protein for 
PD173955. 
In this thesis the data from SELEX experiments to select an aptamer that 
recognizes PD173955 will be presented.  The size of the selected putative aptamer 
was minimized from 78 to 37 nucleotides long.  The selected aptamer binds 
PD173955 with high affinity in intracellular buffer conditions and at a temperature of 
37oC.  PD173955 is an ATP analog, but the selected aptamer has very low affinity 
for adenosine and ATP under the same conditions. 
The selected aptamer binds at least one other insoluble compound that 
belongs in same class of compounds as PD173955. Based on the solubility of the 
compounds that were used and their structures, some conclusions can be made 
regarding the aptamer’s specificity. 
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CHAPTER 2:  SELECTION OF AN RNA APTAMER TO PD173955N THROUGH 
SELEX 
 
INTRODUCTION 
 Using SELEX, an aptamer was selected that can bind PD173955 in water 
based buffers that approximate intracellular salt concentrations.  The aptamer has a 
Kd of 1-3 µM for PD173955 and could be used to target the compound to specific 
cells.  Although PD173955 is an ATP analog, the aptamer has low affinity for ATP 
and adenosine.  However, the aptamer binds with relatively high affinity to another 
compound that is chemically related to PD173955.  This suggests that the selected 
RNA aptamer to PD173955B (Figure 2a, Page 26) might be applied directly as a 
carrier for a range of pyrido[2,3-d]pyrimidines compound. Alternatively, aptamers 
can be further evolved by a procedure called “doping” to alter their specificity for 
related molecules. 
The RNA SELEX was performed in the following way (Figure 3, Page 28).  A 
single stranded randomized DNA pool was synthesized and it was PCR amplified or 
extended to generate the double stranded DNA pool.  Using this DNA pool, RNA 
was generated by in vitro transcription and simultaneously radio-labeled for easier 
tracking.  The radio-labeled RNA was mixed with the PD173955B.  The RNA/target 
complexes were separated from non binding RNA molecules using a filter 
apparatus.  Then the RNA was reverse transcribed and PCR amplified to generate 
 the dsDNA pool for the next round.  After sufficient binding or no increase in binding 
from previous rounds was achieved, the PCR amplified dsDNA pool was cloned and 
sequenced.  The sequences were aligned and families identified as p
aptamers.  The affinities of the putative aptamers for
Page 26) were checked by is
 
Figure 2:  The structures of several pyrido[2,3
Structures of (a) PD173955B, (b) PD173955N, (c) 4
propionylamidoquinazoline (PD174265), and (d) adenosine.
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traditional method to select an aptamer was used.  This method involved covalently 
attaching PD173955N to Sepharose 4B beads and making a small column that was 
used for the selection procedure.  By using this method three problems appeared.  
First, nonspecific binding was high so more then 50% of the RNA molecules bound 
to the beads that didn’t have any PD173955N attached.  The second problem was 
that the beads had too many reactive groups for PD173955N attachment and the 
concentration of PD173955N was not easily controlled.  Covalently attaching lower 
concentrations of the target to the Sepharose 4B beads was unsuccessful.  The third 
possible reason why this selection was unsuccessful may have had been due to the 
complexity of the initial random pool.  To prepare the initial dsDNA random pool only 
a small portion of the ssDNA pool was PCR amplified, which resulted in multiple 
copies of a subset of the molecules in the initial dsDNA pool.  In the later successful 
selections DNA extension instead of PCR was used to generate the initial dsDNA 
pool.  The advantage of using DNA extension over PCR amplification is that the 
complexity of the initial double stranded pool is retained.  A disadvantage of that is 
the copy number of the each dsDNA molecule is lower.   
Another unsuccessful attempt at SELEX involved selections of the RNA 
aptamers using Streptavidin beads that were pre-coated with the biotinylated 
PD173955B (Figure 2a, Page 26) derivative.  After six rounds of selection no 
enrichment was observed and these selection experiments were stopped.   
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Figure 3: RNA SELEX.  The basic procedure for RNA SELEX is shown. 
 
MATERIALS AND METHODS 
DNA library construction 
The DNA oligonucleotide template library named Oligo 487: 
5’-GCCTGTTGTGAGCCTCCTGTCGAA(53N)TTGAGCGTTTATTCTTGTCTCCC-3’ 
with N symbolizing an equimolar mixture of A, C, G, and T, was synthesized 
(Integrated DNA Technologies, Coralville, IA).  The oligonucleotide primers used in 
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reverse transcription and PCR experiments had the following sequences: Oligo 484: 
5’-TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3’ and Oligo 485:  
5’-GCCTGTTGTGAGCCTCCTGTCGAA-3′.  All pH values cited in this thesis were 
measured at 23oC.  For the first round of SELEX double-stranded DNA pools were 
generated in the following way.  Twenty four 100 µl reactions containing 1.67 µM of 
Oligo 487, 0.5 mM dNTP, 3.33 µM oligo 484, and 0.03 U/µl DNA Taq Polymerase 
(GenScript) in 50 mM KCl, 10 mM Tris HCl (pH 8.55), 1.5 mM MgCl2, 0.1% Triton X-
100 were incubated at 95 °C for 10 min, at 65 °C for 30 min, and at 72 °C for 99 
minutes using the Multi GENE II PCR minicycler.  The generated dsDNA was 
ethanol precipitated by adding 2.5 volumes of 100% ethanol and 0.1 volume of 3 M 
NaOAc and incubated at -80 °C for 30 minutes.  The sample was centrifuged for 15 
minutes and the precipitated dsDNA was dissolved in 120 µl ddH20 (distilled, 
deionized water).  The dissolved dsDNA was resolved through a 12% PAGE in TBE 
(90 µM Tris-Borate, 2 µM EDTA, pH 8.5) to separate the primer and the ssDNA that 
was not extended.  The top band was cut out, crushed, and eluted overnight at 37 
°C in 300 mM NaOAc, 10 mM EDTA, pH 8.  The eluted DNA was phenol/chloroform 
extracted and ethanol precipitated to remove polyacrylamide contaminants.  The 
pellet was resuspended in 90 µl of ddH20 and the dsDNA quantified by measuring 
absorbance at 260 nm. The 260/280 ratio was used to monitor the purity of dsDNA. 
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RNA synthesis and purification 
RNA was prepared by in vitro transcription using the AmpliScribe™ 
T7-Flash™ Transcription Kit (Epicentre, Madison, WI).  The transcription reaction 
was carried out at 37 °C for 4-6 hours.  For the “body-labeled” RNA, 166 nM of α-P 
32
-ATP in combination with 7.5 mM of each NTP (ATP, UTP, CTP, GTP) was 
included in the reaction mixture.  Following DNase digestion (1 MBU per 20 µl), the 
RNA was ethanol precipitated by adding 2.5 volumes of 100% ethanol, and 0.1 
volume of 3 M NaOAc and incubated at -80°C for 30 minutes.  The sample was 
centrifuged for 15 minutes and the precipitated RNA was dissolved in 8 M urea.  The 
dissolved RNA was resolved through a 10% denaturing PAGE gel containing 7 M 
Urea in TBE at 200-300 volts.  The band was visualized under a UV lamp, excised, 
gel crushed, and eluted overnight at 37 °C in 300 mM NaOAc, 10 mM EDTA, pH 8.  
The gel slices were centrifuged at top speed (Eppendorf, model 5415D), the 
supernatant containing the RNA was removed and the RNA ethanol precipitated.  
The RNA was resuspended in DEPC H2O (0.01% diethyl pyrocarbonate in dH20, 
autoclaved at 120oC for 1 hour) and quantified by measuring the absorbance at 260 
nm.  The 260/280 ratio was used to check the purity of the RNA. 
 
Determination of the molar extinction coefficients of the PD173955 derivative 
Amino labeled and biotin labeled derivatives of PD173955 were synthesized 
by Dr. George Kraus’ lab (ISU, Ames, IA) (referred as PD173955N and 
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PD173955B), dissolved in 100% DMSO and stored in -20oC until use.  PD174265 
was purchased from Calbiochem (San Diego, CA), and stored in 100% DMSO 
at -20oC (Figure 2c, Page 26).  Adenosine was from Sigma (St. Louis, MO), and ATP 
was from Epicentre (Madison, WI).   The structures of the compounds were drawn 
using WinDrawChem available at http://xdrawchem.sourceforge.net/windrawchem/. 
The molar extinction coefficient (ε) for PD173955N was determined by UV 
absorbance based on Beer’s Law (A=εcl), where c stands for the molar 
concentration and l stands for the path length, which was 1 cm.  A known mass of 
PD173955N was dissolved in 50% ethanol and 50% DMSO.  The solution containing 
PD173955N was scanned from 200 to 800 nm using UV Spectrophotometer 
(Biowave, model S2100, WPA, Cambridge, England).  The UV absorbencies were 
read of increasing concentrations of PD173955N.  The absorbance readings vs. the 
concentrations of PD173955N were plotted using Microsoft Excel and ε was 
calculated.   
 
Mathematical simulation of SELEX 
Mathematical simulation of SELEX was used to set the optimal initial 
concentrations of the RNA pool and PD173955B  (Levine and Nilsen-Hamilton 
2007).  The simulation model predicts the least number of selection rounds 
necessary to reach 100% of possible binding species based on the user input.   For 
the simulation to work, the user needs to know the KD of the initial RNA aptamer 
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pool, the approximate KD of the best binding RNA aptamers within the pool, and the 
background binding of the initial pool. 
 To use the model the initial pool was grouped into 15 binding groups of 
aptamers with Group one having highest affinity for the target and the Group 15 the 
lowest.   The advantage of using the model is that the user can set the selection 
pressure on the SELEX by changing the percentage of the target reduction with 
each additional round and see the simulated results.  If the percent of the target 
reduction is set too high, no selection is observed, or it may take many extra rounds 
for the binding species from Group one to reach maximum percent bound.  Also, if 
the background (everything else except target) is set too high, one may never obtain 
the maximum amount of the binding species. 
A computational analysis was used to predict initial conditions, which required 
the insertion of estimates of the dissociation constant of the initial pool and of the 
aptamers to be selected.  The affinity of the original pool for PD173955N and the 
percentage of the background binding were determined experimentally.  Because 
PD173955 is an ATP analog, the best KD of the aptamer to be selected was 
predicted to equal 1 µM, which is in the same range as for the ATP RNA aptamer (5-
8 µM) (Sassanfar and Szostak 1993; Sazani, Larralde et al. 2004).     
 
In vitro selection 
SELEX was principally performed as described by Tuerk and Gold (Tuerk and 
Gold 1990).  Briefly, “body” radio-labeled RNA was dissolved in selection buffer 
(300 mM KCl, 5 mM MgCl2, 20 mM HEPES, 5% DMSO, pH 7.5).   
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Approximately 8000-16000 ultralink immobilized streptavidin beads (Pierce, 
Rockford, IL) were washed with 1 ml of selection buffer, by resuspending the beads 
in the selection buffer and spinning them down 2-3 times and discarding the 
supernatant.  In the first selection round 0.5 nmoles of the S.R0 RNA pool in 
selection buffer was mixed with 1 nmole of PD173955B at 23 °C in 1 ml reaction. 
The binding reaction was performed by slowly agitating the mixture by 
rotation at 23 °C for 30 minutes.  Afterward, 16,000 prewashed immobilized 
streptavidin beads were added to the binding reaction and the reaction was 
incubated for an additional 30 minutes to capture the RNA/PD173955B complex.  
The mixture was filtered though a 0.44 µm filter on filter apparatus and washed 1 
time with 1 ml of the selection buffer.  The bound species were eluted with 8M urea 
at 95 oC and 1 ml fractions collected.  The elutions were pooled, ethanol precipitated 
as described above, and dissolved in 20 µl of DEPC ddH20.  Due to the low 
concentrations of RNA in the collected elutions, linear polyacrylamide (Sigma, St. 
Louis, MO) was used as carrier to help better precipitate the RNA.  The precipitated 
RNA was reverse transcribed using SuperScriptTM III RNase H- and reverse primer 
Oligo 485, (Invitrogen, Carlsbad, CA) in 50 mM Tris-HCl 75 mM KCl, 3 mM MgCl2, 
5 mM DTT (pH 8.3), at 50oC for 1 hour and the reaction was stopped by incubating 
at 70oC for 15 minutes.  One half of the reverse transcription reaction was PCR 
amplified in 100 µl PCR reaction (50 mM KCl, 10 mM Tris HCl, 7.5 mM MgCl2, 
0.1% Triton X-100 Buffer, 2 µM primers, 1 mM dNTP, 0.5 U/µl Taq DNA Polymerase 
(pH 9.0) for 12-14 cycles, 3 minutes at 93oC, 30 seconds at 93oC, 1 minute at 65oC, 
1 min at 72oC, and 5 minutes at 72oC.  The other half the reverse transcription 
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reaction was saved in case the PCR didn’t work or the in vitro transcription was 
unsuccessful.  To help increase mutations in the pool, 7.5 mM MgCl2 and 1 mM 
dNTP were used in the PCR reactions.  After each PCR amplification, the PCR 
product was resolved on 2% agarose in TAE buffer (40 µM Tris Acetate, 1 µM 
EDTA, pH 8) to verify the size of the amplicon.  For negative selections, RNA pools 
were incubated with the streptavidin beads for 30 minutes to remove RNA species 
that bind specifically to the beads and the filter. The beads were washed once with 
1 ml of selection buffer, and the flow-through and wash fractions were pooled and 
ethanol precipitated and the RNA was dissolved in the selection buffer.  The 
dissolved RNA was mixed with PD173955B in the selection buffer and the next 
selection round was performed as above.  Two SELEX experiments, named S569 
and S570 were performed in parallel.  After the first round in each SELEX 
experiment, the concentration of PD173955B was reduced either by 0 or 10% in 
each additional round.  After the 12th round of S570 and the 8th round of S569, the 
ssDNAs were PCR amplified as described previously, and cloned into pcDNA 3.1 
using the Directional TOPO expression plasmid kit (Invitrogen, Carlsbad, CA).  The 
plasmids were chemically transformed into One Shot bacterial cells (Invitrogen, 
Carlsbad, CA), and the bacteria were grown in SOC media (2% Tryptone, 0.5% 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose) for one hour with shaking (250 rpm).  The transformation mix was plated on 
LB (15g/l Bacto Agar, 10 g/l Bacto Tryptone, 5 g/l yeast extract, 10 g/l NaCl) culture 
plates with ampicillin resistance (50 :g/ml) and grown overnight in 10 ml of LB at 
37oC.  Individual clones were picked and grown overnight in 10 ml of LB (50 :g/ml 
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ampicillin) at 37oC with shaking (250 rpm).  Plasmids were extracted from 3 ml of 
each bacterial culture using the QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA), 
and the plasmids sent for DNA sequencing (ISU DNA facility, Ames, IA).  Sequences 
of the inserts within the sequences were found using Biology WorkBench, and 
aligned using BioEdit software (obtained at: //workbench.sdsc.edu/ and 
www.mbio.ncsu.edu/BioEdit/bioedit.html).  The nomenclature given the clones 
obtained from the SELEX experiments is as follows.  S###R##C##, where the first 
number is that assigned to the SELEX experiment, R## is round number, and C## is 
the clone number.   
 
Measurement of binding affinities of the putative aptamers 
The affinities of the selected aptamers to PD173955B were measured in 
solution by isothermal titration calorimetry (ITC) on a VP-ITC instrument (MicroCal, 
Northampton, MA) at 37 °C or 25 °C.   Prior to performing the ITC experiments, the 
RNA aptamers were denatured at 90 °C for 5 minutes and slowly refolded at 23 °C 
for 30 minutes. The RNA and the solutions containing binding partners were 
degassed at 20 °C for 5 minutes using the VP-ITC ThermoVac accessory (pulling a 
vacuum of 28.4 inches of mercury).  A 300 µl solution containing one of the binding 
partners was injected from the syringe in 10-µl portions for 6 sec durations with each 
injection, and at 5-10 minutes intervals between the injections for equilibration.  
Dilution experiments were performed in the absence of one of the binding partners in 
the cell compartment of the ITC instrument.  After each injection, the generated heat 
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of the binding reaction was recorded.  ITC binding curves were analyzed by using 
the MicroCal Origin software package.  
 
RESULTS AND DISCUSSION 
Determination of molar extinction coefficient  
 To have a more convenient means of determining the concentrations of 
PD173955N in solution, the molar-extinction coefficients were calculated.  
PD173955N was dissolved in chloroform and transferred into a microcentrifuge tube.  
The chloroform was evaporated and the mass of the tube was recorded.  The dried 
PD173955N in the tube was dissolved in 50% ethanol and 50% DMSO.  When the 
absorbance between 200-800 nm was read using the UV-Spectrophotometer, two 
peaks were observed (Figure 4, Page 37).  Prior recording all the readings, solution 
of 50% ethanol and 50% DMSO was used as reference.  The UV-
Spectrophotometer unit automatically subtracted the reference readings.  One peak 
was observed at 299 nm and the other at 354 nm.  The molar extinction coefficients 
for both wavelengths were calculated and they are 8525 and 16504 M-1cm-1 
respectively.  This experiment was repeated twice and the same molar extinction 
coefficients for PD173955N were obtained.  These values were used later to 
estimate the concentrations of PD173955N.   
 Figure 4: UV absorption spectrum
PD173955N in 50% ethanol and 50%DMSO measured from 200
extinction coefficients were calculated by graphing a known concentrat
50% ethanol and 50% DMSO against the collected absorbance readings at 299 and 354 
nm. 
 
Selection of RNA aptamers
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RNA to the filter and the streptavidin beads was determined experimentally as 3% of 
the total RNA.  Using these three parameters, the simulation program returned the 
least number of rounds of selection necessary to select the aptamer if the initial 
concentration ratio was set to be 2 µM PD173955B and 1 µM RNA.  With the 
reduction in the target concentration set to 10% in each round, the model predicted 
that at least 5 selection rounds would be necessary to achieve optimal selection 
(Figure 6a, Page 41).  These conditions were used for S570.  For the S569, the 
same concentrations were used, but the reduction of the target concentration was 
set to zero, and the simulation model predicted that at least 7 rounds were 
necessary (Figure 7a, Page 43).   When these two figures are compared, the 
mathematical simulation modeling suggested that increased pressure on the 
selection should help reduce the number of necessary rounds. 
In the S570 12 positive rounds and 2 negative rounds were completed before 
the PCR product was cloned and sequenced.  After 8 positive rounds, the amount of 
RNA bound has increased to 14% (Figure 6b, Page 41).  After four more positive 
rounds and one negative selection round there was no increase in the fraction of 
captured potential RNA aptamers (Figure 6b, Page 41).  
The simulation model predicted that only 5 selection rounds were necessary 
to reach a maximum percent of the RNA bound.   It can be seen on the Figure 6b 
(Page 41) that the maximum percent of RNA bound was reached after 8 rounds. 
 
 Figure 5: ITC titration of PD173955N with the initial random RNA pool. 
titration of 46 µM PD173955N with the 6.5 µM random RNA pool in 
150 mM KCl, 0.22 mM Na2HPO
MgCl2, 20 mM HEPES, 6 mM glutathione, pH 7.25
into buffer A. The data in (b) 
calculate the KD. The KD, calculated by the Origin software
of both graphs represent raw ITC profiles obtained.  The lower section of the graph in (a) 
shows the subtracted data, and in (b) shows the raw ITC data.
 
The PCR amplified pool from positive round 12 was cloned.  Fifty clones were 
picked, grown overnight and their plasmids extracted and sent for sequencing.  Of 
the fifty picked clones only 43
shorter in the randomized regio
have been due to deletion during PCR amplification because of strong 
39 
buffer A (
4, 0.44 mM KH2PO4, 100 µM MgSO4, 120 nM CaCl
) at 37oC, and (b) the PD173955N dilution 
was subtracted from the data that was obtained in (a)
, was 50 mM.  The upper sections 
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structures where the DNA polymerase was not capable of amplifying.  Another 
possibility is that melting of the RNA molecules was not complete because of the low 
incubation temperature during reverse transcription.  During the SELEX experiments 
it was observed on the gel images that the size of the PCR amplicon and the 
transcribed RNA was decreasing as the number of rounds increased. 
In S569, 12 positive and 4 negative selection rounds were performed.  
According to the simulation model, seven rounds would be necessary to reach a 
maximum fraction of the RNA aptamers bound.  The data obtained experimentally 
are shown in the Figure 7b (Page 43).  In the eighth round of the SELEX experiment, 
25% of the RNA pool bound to the target.  Further rounds failed to preserve the high 
percentage of the RNA pool bound to the PD173955B.  The percent bound in the 
12th round was about the same that was observed in S570.R12. 
Because the highest percentage bound was observed in round 8, it was 
decided to clone the PCR product obtained after the reverse transcription of the 
bound RNA in round 8.  One hundred clones were picked and sequenced.  Out of 
the 100 picked clones 96 sequences were obtained.  The random derived regions of 
the obtained sequences are listed in Table 3 (Page 51).  As can be seen from the 
table most of the sequences have the full length random region, unlike in S570 
(Table 1, Page 47) where the majority of the sequences were truncated.   
 Figure 6:  Computational prediction and progress of S570. 
S570 and (b) progress of S570.  
black bars represent negative selections.
against the selection round number.  The table below t
values obtained in each round.  
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Alignment of the sequences from both SELEX experiments revealed a 
number of repeated sequences in each SELEX experiment (Table 1, Page 47 and 
Table 3, Page 51).  Two small families of putative aptamers were obtained.  All 
identified sequences except one had a decreased number of nucleotides in the 
randomized region in S570.  Four clones in S570 that displayed identical sequences 
(Clone 10) were classified in the first family.  S570.R14.C32 RNA is a member of 
family one except it contains a single base insert within the random region (Table1, 
Page 47).  The same sequence was repeated six times in S569 (S569.R8.C43).  
The two most stable secondary structures predicted by M-fold of the S570 R14.C32 
RNA are shown (Figure 8a, Page 44).  The second smaller family was mostly 
present in S569 (S569.R8.C15).  It has the same sequence as S570.R14.C47.  
These were classified as the second family of aptamers.  The consensus sequences 
of the family one and the family two aptamers are not related to that of the reported 
ATP RNA aptamer (Sassanfar and Szostak 1993; Dieckmann, Suzuki et al. 1996; 
Vaish, Larralde et al. 2003).   The sequence and the secondary structure of the ATP 
RNA aptamer predicted by M-fold is shown in Figure 8b (Page 44).  As it can be 
seen on Figure 8a and b (Page 44) the aptamer representing family one of the 
sequence, and its predicted secondary structure is different from that of the ATP 
RNA aptamer.  Clones 23, 25, and 31 also had identical sequences, representing a 
second family of aptamers.  The binding affinities of these clones were determined 
using ITC. 
43 
 
 
Figure 7:  Computational prediction and progress of S569. (a) Computational analysis of 
S569 and (b) progress of S569.  The 3D white bars represent positive selections, and the 
black bars represent negative selections.  The percentage of RNA bound was plotted 
against the selection round number.  The table below the graph in (b) shows numerical 
values obtained in each round.   
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 Determination of dissociation constants of putative RNA aptamers
 The dissociation constants of the selected putative RNA aptamers for 
PD173955N were determined by isothermal calorimetry (ITC) and they varied from 
2-11 µM (Table 2, Page 49
between 2-3 µM for PD173955N, and the aptamers from family two had K
11 µM (Table 2, Page 49
µM, was chosen for further studies, because it gave the 
Representative ITC data obtained f
 
Figure 8:  RNA secondary structures predicted by the M
the most stable structures of S570.R14.C32RNA, and (b) 
aptamer.  All structures were determined by M
44 
).  The aptamers from family one had K
).  S570.R14.C32RNA, with a dissociation constant of 2 
lowest dissociation constant.  
or S570.R14.C32 is shown (Figure 9
-fold.  Shown are (a) the two 
the structure of the ATP RNA 
-Fold. 
 
Ds ranging 
Ds around 
a, Page 45).   
 
  Binding of S570.R14.C32 to ATP and adenosine using ITC was checked 
under similar ITC condition
PD173955N.  The aptamer did not s
used, and from the ITC data obtained it was not possible to calculate a K
and adenosine (Figures 10 and 11
that the secondary structure of the aptamer does not resemble any part 
ATP aptamer (Figure 8, Page 44
 
Figure 9: Determination of thermodynamic parameters by ITC.  
of 28 µM S570.R14.C32 RNA into a solution containing 4 
reference data was subtracted, (b) 
This experiment was repeated 
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µM PD173955N after the 
the reference data with PD173955N titrated into buffer.  
five times with similar results each time.    
D for ATP 
of the RNA 
 
  We wanted to further test 
to other compounds that are similar in structure to PD173955.  Using ITC the binding 
of 4-[(3-Bromophenyl)amino]
to the full length aptamer S
member of the pyrido[2,3
kinase inhibitors (Tulasne, Judd et al. 2001)
in water based buffers.  The dissociation constant of S570.R14.C32 
20 µM (Figure 12, Page 50;
the software, the ITC data for 
evidence of a titration. This suggests that S570.R14.C32 RNA aptamer 
bind PD174265.  
Figure 10: ITC titration of ATP with S570.R14.C32RNA. 
ATP with µM S570.R14.C32RNA in 300mM KCl, 20 mM HEPES, 5 mM MgCl
pH 7.5 at 37 oC, after the data for separate titration of  ATP dilution into buffer was 
subtracted.  The analyzed data on the bottom half of the graph shows no binding 
46 
the specificity of the S570.R14.C32 RNA aptamer 
-6-propionylamidoquinazoline (PD174265, Calbioch
570.R14.C32 RNA was determined.  PD174265 is a 
-d]pyrimidine family of compounds which are Src family 
 and like PD179355N is not very sol
for PD174265 is 
 Table 2, Page 49).  Although a Kd was determined
PD174265 and S570.R14.C32 does not show 
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S570.R14.C32 RNA to ATP under these conditions.  This experiment was repeated twice 
with similar results each time.    
 
Table 1:  The sequences of 43 clones from the 12th round of S570.  Under “Name” is 
the sequence number, and under “No” is the number of times the sequence is repeated.  
The primer sequences are not shown. 
 
 If the structures of PD173955N and PD174265 are compared, it can be 
seen there are some similarities and crucial differences between two of them 
(Figure 2b and c, Page 26). PD174265 is a smaller compound then PD173955N.  
 They both contain three benzene rings that are spaced similarly and have a purine 
moiety in the main part of the molecule.  
For example, the  bromobenzene ring that is further away from the purine part of the 
molecule in PD174265 has a 
structure are consistent with
not PD174265. 
 
Figure 11: ITC titration of adenosine with S570.R14.C32RNA. 
100 µM adenosine with 8 µM S570.R14.C32RNA 
MgCl2, pH 7.5 at 37 oC after 
subtracted.  The data shows no binding of S570.R14.C32RNA to adenosine under these 
conditions.  This experiment was repeated twice
48 
But, otherwise their structures are different.  
than it is in PD173955.  These large differences in 
 the observation that the aptamer binds 
 
Shown is the titration of 
in 300mM KCl, 20 mM HEPES, 5 mM 
the data for separate titration of adenosine into the buffer was 
 with similar results each time
PD173955 and 
.    
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Table 2: Dissociation constants of the tested aptamer sequences determined by ITC. 
 
 During the SELEX experiments, the biotin/streptavidin system was used to 
capture the RNA/PD173955 complex.  The biotin part of PD173955B was bound to 
the streptavidin binding pocket (Figure 2a, Page 26).   If the aptamer pools were 
binding to the biotin part of PD173955B then the RNA/PD173955B would not been 
captured by the streptavidin.   The S570.R14.C32 RNA aptamer does not bind ATP 
or adenosine under ITC conditions tested.  PD173955 is an ATP analog and the 
purine part of the molecule resembles the structure of the adenosine (Figure 2d, 
Page 26).  Adenosine has nitrogen that could interact with the PD173955N aptamer, 
but the ITC data does not show binding of adenosine to the S570.R14.C32 RNA 
aptamer, therefore the nitrogen does not have a significant role in binding to the 
aptamer.  The purine part of the molecule does not have a benzene ring attached to 
it, but from the structural comparison, the benzene ring is not very important in 
binding of PD173955N with the aptamer.  It is very difficult to determine which parts 
of the target molecules the selected aptamer binds, because the RNA aptamer 
makes a number of contacts with PD173955N.  Most aptamers are believed to bind 
Sequence No. PD173955N 
Dissociation 
Constant (µM)
PD174265 
Dissociation 
Constant (µM)
SELEX570.R14.C32 1.2± 0.8 20 Family I
SELEX570.R14.C10 2.5 Family I
SELEX570.R14.C32T2 1 40
SELEX570.R14.C10T1 57000
SELEX570.R14.C47 26 Family II
SELEX570.R0 50000
 their targets through the induced fit model.  
adenosine was confirmed by ITC
of adenosine with the S570.R14.C32 RNA aptamer does not protect the aptamer 
from RNase ONE cleavage
present (Figure 16a and b, Page 64
 
Figure 12: ITC titration of PD174265 with S570.R14.C32RNA. 
75 µM PD174265 with 5 µM S570.R14.C32RNA in 300mM KCl, 20 mM HEPES, 5 mM 
MgCl2, 5%DMSO, pH 7.5 at 37
was subtracted. The KD, calculated by the Origin software 
repeated twice with similar results each time
50 
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 in the region where it is protected when PD173955N is 
).   
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Table 3:  The sequences of 96 clones from the 8th round of S569. Under “Name” is the 
sequence number, and under “No” is the number of times the sequence is repeated.  The 
primer sequences are not shown. 
Name No.
15 4 - - - - - - - - - - - - - - - - - - - A T C A A A A C - - - - A C A A A G A G G A C T C A C A A A A C A - - - - - - - - - - - - - - - - - -
45 1 - - - - - - - C A A T C A G G A A A T A T C A A A A C T C G A A C G G A G A G G A C G T A G G A A A G A G G A C A G G T - - - - - - - - - -
30 1 - - - - - - - - C G G G A A G A A G G G G G A A A A G A A C A A A A G G A G G A C G G - A C A A A A G A G A G A G A A A G A - - - - - - - -
29 1 - - - - - - - - G G A G G A C A G T G G G C A A A G C A A C A A A A G A A G G A G A G - G G G A A G G A G G G G G A C A G A - - - - - - - -
21 1 - - - - - - - - - C G A C G C A G G G A C A G G A A C A A G A G C C G A A G G G C A A C A G C A A G G A G G G A A A A A G G - - - - - - - -
91 1 - - - - - - - - - T T G A C C A A G A C C C A C A G A C T A G A C A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
53 1 - - - - - - - - - - - - C A C A A G A A C G A C G G A A C A A A G A A G C G A G C G T G C A C G G A A C A G G A C A G G A C C G A - - - - -
72 1 - - - - - - - - - - - - - C A C A G T C C A T C A G A C A G G A A A G A C T C G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
49 1 - - - - - - - - - - - - - - G A A T C A C A G C A G A - A A G A G A G A C A C G T G G G A A C G G G A G A G G A G A C A C A G A A A A G - -
27 1 - - - - - - - - - - - - C G A A A A A N C G A G G T C A C A A A G C A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
25 1 - - - - - - - - C C A G C G G A A A G C A A G G A G G A C A A A A G G A A G G G A A G G T G G G G A G A C G C A A A G A G - - - - - - - - -
93 1 - - - - - - - - - - G C A A A G A A A T C A C A A G A A G G G G C G A T C A A C G A A C G A G G G C A A G C A A A A A G G G A - - - - - - -
86 1 - - - - - - - - - - - - - - - - - - - T C G C G A T C A A A A - C G A A C A A C A - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
64 1 - - - - T A C T C A C A C C G A G A A G C A C T A T C G C A A - C G C A A A A A A G A A G - - - - - - - - - - - - - - - - - - - - - - - - -
50 1 - - - - - - - - - - - - - - - - - - - - A G T C G G C G A A A - C G A A A A A C A T A A G A - - - - - - - - - - - - - - - - - - - - - - - -
28 1 - - - - - - - - - G G C G C C G A A G C C C A A A A G G G A A C C A C C C A G A A A A C A A G T A G A C A G G G G G A A C G - - - - - - - -
24 1 - - - - - - - - - - - - - - - - - - A C T C A C A A A G - - A G T A A C C A A A A A C A A T T T C G A - - - - - - - - - - - - - - - - - - -
43 6 - - - - - - - - - - - - T T C G A A A T C G C A C A G T - A A A C T C A C A A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
37 1 - - - - - - - - - - - - - - - - - - - T C G C - C A G T - T A G A T C A C A A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
39 1 - - - - - - - - - - - - - - - - - - - T C A A A C A G T T A A A C T C A C G T T T - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
38 1 - - - - - - - - - - - - - - - T C C A C C A A C A A A G A G A A C T C A C C A C C C A - - - - - - - - - - - - - - - - - - - - - - - - - - -
52 1 - - - - - - - - - - - - - - - - C T A A C A C A C A C A G A A T C T C A C A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
44 1 - - - - - - - - - - - - - - - - G G C A C A C G A G C G C A A T T T C T C A A G G C G G C G G A A A G G G A N C G G G G C G A C G A A A T G
34 1 - - - - - - - - - - G G G A C A - G G A C G T C C A A C T A A A G G T - G A A C G G A A G T G C A A A T A T T A A C A C T A C G G - - - - -
10 1 A C G G T C G T A G A G G A C A A G G A A G C C C G A T T A A A G G T C G A A G A G A A G G G G A T G C A - - - - - - - - - - - - - - - - -
7 1 - - - - - - - - - - - - - - - - - - - - - - - A C A G T T T A G T G C - A A A C A G A A A A A C G - - - - - - - - - - - - - - - - - - - - -
8 1 - - - - - - - - - - - - - - - - - G A C C A G C C A A C A T G A C G C A A A C G G G A A G T A G A T G C A A - - - - - - - - - - - - - - - -
77 1 - - - - - - - - - - - - - - - - - - - - A C C T C C G T T T A A G A C - G A C G A G A C T C A C A A - - - - - - - - - - - - - - - - - - - -
87 1 - - - - - - - - - - - - - - - - - T A C C A C G A A A C G C A - - G - A A A A C T C A C A - - - - - - - - - - - - - - - - - - - - - - - - -
70 1 - - - - - - - - - - - - - - - - - T A C C A C G A A A C G C A - - G - A A A A C T C A - - - - - - - - - - - - - - - - - - - - - - - - - - -
36 1 - - - - - - - - - - - - - - - - - - A A C G C G T A A C G A A A G G - A C A A C T C A A C A C A A - - - - - - - - - - - - - - - - - - - - -
9 1 - - - - - - - - - - - - - - - - - G A A C T C A T C A A A A G A G G - G A A A G T C A A - - - - - - - - - - - - - - - - - - - - - - - - - -
6 1 - - - - - - - - - - - - G C C A A G A C C T C C A A G G A A G A G G A G A A A G C C A G A G G G A G A G A A G C A A A C G A C G T - - - - -
94 1 - - - - - - A G C G A C A A A G G C G G A G A C A A C C G A G C C G G G G A A T A A A G C G C T A A A G G G C A G A G - - - - - - - - - - -
47 1 - - - - - - - G G G A C A A T C A G G A G G A G G A A C - A G C G G G A G C A G A A G G C G A T A A G A - - - - - - - - - - - - - - - - - -
71 1 - - - - - - - - G C G C G G A G A A G C A G - C G A C G A G G A A G G A G G A G T A C G C A A C A A G A G G C A G A G G A G - - - - - - - -
19 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - G G G G G A C A A A C A G T - - - - - - - - - - - - - - - - - - - - - -
56 1 - - - - - - - - - - - - G G A C G A A G A G G G A A C A A G G G A A A G G G A G G C A A A A C - A G A G C G T C G A G G G A A - - - - - - -
35 1 - - - - - - - - - C G A A C A G G A A G A A G A G G A C C A G G A A C G G G A C G C G A G A C C A A A T C G T C C T C A A C - - - - - - - -
90 1 - - - - - - - T C C G T A C A G G A A A A A C A C G T C C A G A A A A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
46 1 - - - - - - - - A A A G A G G T G C A G C A A A A G A A G A - A A C A C G A A A C G G G C G A C G G C A A A A A A C G A A A G - - - - - - -
22 1 - - - - - - - - - - - - - - - - - - - - - G C G A G G A A G - A A T T C G A A A C - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
58 1 - - - - - A C G A G A C C C A A A A G G C G C G A G G A G G T A G C A G A A A G C C G G G C A A A G C A G G T A G G - - - - - - - - - - - -
88 1 - - - - - - - - - C A C C A A C A G A A G A A A G G A C A G G G A C G A G A A G A C A G G A A T A A G A G G G A A C A G G A - - - - - - - -
95 1 - - - - - - - - - - - - - - - - - - - - - - - G C A G C G A C T C A C G G A A C C A A A A T C G G G A A G A - - - - - - - - - - - - - - - -
48 1 - - - - - - - - - - C G A C G G C G A G T C A A A G G C G A G A G A G G G A A A C A A A - - C G G A A A G A A A A G A G G A A C G - - - - -
26 1 - - - - - - - - - - - - - - - - - - A C A C A A A G G C A - C A C A G T G A A C A - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
11 1 - - A A G C G A G A C G A G A G C C G C A C G G A G G C A A C A A A G A G G A C G A A A G A G G G G A G A G - - - - - - - - - - - - - - - -
81 1 - - - - - G A C T C A G C C G A G A G C C C G G A A G C G - C A G G C G G G A A G A A A G C G C C A A G T G G C A G A - - - - - - - - - - -
18 1 - - - - - - - - - - - A C G A A A G T C T C G G A A G C - - - - G A C A G G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
96 1 - - - - - - - - - - - - - A C T A G A A A G C A G - - - C A C - G C A A G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
20 1 - - - - - - - - - A C G C A C T C G A C A A T A G - - - C A C A G C A A C A C C G C C T C G A A C A G C C A A C A A T A G C G T C - - - - -
32 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T G C C T T T A A C C T C C A C - - - - - - - - - - - - - - -
68 1 - - - - - - - - C A C G C A G C C G A G A A G G G A C C C A C C T C A G G A A G G A G C A C A A A A G C G A A T C A G G G - - - - - - - - -
89 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A A C T C A C A T T T T G T C T C T - - - - - - - - - - - - - - -
79 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T C A G G A C T C A C T T T T T T T T T T T - - - - - - - - - - - - - - -
83 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T C A G G T T C C C A C T T T T C T C A A - - - - - - - - - - - - - - -
12 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A T C A G G A T A C T C A C A T T C A C C G - - - - - - - - - - - - - - - -
75 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - C A T G C - - - - - - - - - - - - - - - -
1 1 - - - - - - C G G A A T G G C T C C G G G G A A A G A T A A C C C G C A A A A T C C G T C T T G T C A C G C A C G T A - - - - - - - - - - -
57 1 - - - - - - - - - - - - - - - - - - - - - G C G G G G G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
14 1 - - - - - - - A A C C A A A - - G C C C C G C G G G G G T A G A G G G G C A A C C A C T A C A C A G A C G C A A A T A G A C - - - - - - - -
16 1 - - - - - - - A T C C G T A C G G G G G T T C G C A A C T A C A C G A G A A A A T A G T A C T T T C A C A A A A C T G C - - - - - - - - - -
61 1 - - - - - - - G G C A A G G C A C A T G A C C C G G A G A A C A G G G G C - - C C A C T A C G G G A C C A G A A C G C A G T - - - - - - - -
85 1 - - - - - - - - - - - A G T T G G G A G T C T A G A G G G T C G G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
17 1 - - - - - - - - - - A A G T G G T T A C T C T C G G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
67 1 - - - - - - - G G A T G G C C A G G A G G G C A G A G G G G C C G G A A G A A G C A A G A C A G G G C A A G C G A G G C - - - - - - - - - -
55 1 - - - - C G G G G A A G A G G A G G G G G C C A G A G G C A C T G C A G - - - G C A A G A G T C G G C A C A C A A G G G - - - - - - - - - -
Random Region Sequence
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CONCLUSION 
 The SELEX method is an efficient way to generate an RNA aptamer to a 
small compound.  The conditions used in the two SELEX experiments reported here 
can be used to select RNA aptamers to a number of small compounds.  The 
mathematical simulation model can be used as a guide to set the initial SELEX 
conditions.  Also, it can be used to approximate the number of the selection rounds 
that one needs to do before seeing an increase in binding of the RNA pool.  The 
simulation modeling was useful because it recommended selection conditions that 
resulted in two successful SELEX experiments. 
  It is very interesting that oligonucleotides with the same sequences were 
present in both SELEX outcomes. The aptamers that belong to the second family 
that were mostly found in S569 might have been eliminated when the selection 
pressure was applied in S570.  The ITC data shows that the aptamers that belong to 
the second family have 5-10 times lower affinity for PD173955 compared to the 
aptamers that belong to family I. 
 The next step in development of the aptamer is to minimize the size of 
S570.R14.C32 RNA aptamer.  Even though the size of the aptamer was reduced 
through SELEX from 100 nucleotides long to a 78 nucleotides, it is desired to further 
reduce its size to eliminate segments that are not part of the aptamer. The regions of 
the aptamer involved in the binding also need to be characterized.  The M-fold 
software predicted a number of different secondary structures of the selected RNA 
aptamer and the two most stable structures are shown in the Figure 8 (Page 44).  In 
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the next section of this thesis the truncation and characterization of the selected 
aptamer will be described. 
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CHAPTER 3: CHARACTERIZATION OF THE RNA APTAMER TO PD173955N 
THROUGH RNA FOOTPRINTING ANALYSIS 
 
INTRODUCTION 
In chapter 2 it was mentioned that multiple secondary structures were 
predicted by M-fold software (Figure 8, Page 44).  In order to predict the region or 
regions of the RNA aptamer that bind PD173955N it was necessary to determine 
which secondary structure was correct. RNase ONE footprinting analysis of the 
selected aptamer was done to determine which predicted M-fold structure best 
represents the data obtained through footprinting analysis.    
In chapter 1 the reasons were given why it was necessary to minimize the 
size of the selected aptamer, which include higher specificity and affinity of the 
PD173955 aptamer to the target, and being able to chemically synthesize the RNA 
aptamer.  Also it is beneficial to remove non binding conformations, of the RNA 
aptamer which can be achieved through size reduction.  Minimization of the aptamer 
can be done by using a few methods.  Some of methods are: boundary studies, 
enzymatic probing and site directed mutagenesis (Pendergrast, Marsh et al. 2005).   
 In this chapter the results will be described of the studies that were used to 
characterize the selected aptamer and to minimize its size without loss of affinity for 
the target.  The S570.R14.C32 RNA aptamer produced the best binding constant for 
PD173955N, and it was chosen for further analysis and modification.  By the use of 
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RNase ONE probing, the part of the RNA that is making a contact with the 
PD173955N was predicted.  Unlike proteins, PD173955N is a small compound and 
makes fewer contacts with the aptamer, which makes it more difficult to determine 
the binding regions (Sayer, Ibrahim et al. 2002).   
 
MATERIALS AND METHODS 
5’-end labeling of RNA and purification 
 Dephosphorylation of S570.R14.C32 RNA was carried out at  37oC for 30 
minutes in a 50 µl reaction that contained 50 mM Tris-HCl 1 mM MgCl2, 0.1 mM 
ZnCl2, 1 mM spermidine, 0.04 U/µl alkaline phosphatase (Promega, Madison, WI), 
(pH 9.3) and 0.02 mM of RNA.  An additional 0.04 U/µl alkaline phosphatase was 
added and the reaction was incubated for 30 more minutes.  The RNA was 
phenol/chloroform extracted and ethanol precipitated as described previously 
(Chapter 2).  One nmole of the RNA was 5’end labeled with 20 units of T4 
polynucleotide kinase (Promega, Madison, WI) and 100 µCi [γ-32P]ATP (MP 
Biomedicals, Solon, OH) in 70 mM Tris-HCl 10 mM MgCl2, 50 mM DTT (pH 7.6) for 
1.5 h at 37oC in 50 µl.  The reaction was stopped by adding EDTA to a concentration 
of 19.3 mM.  The RNA was ethanol precipitated and purified through a denaturing 
PAGE gel as described previously (Chapter 2). 
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RNA footprinting Assays 
Determination of enzymatic probing conditions 
 The necessary RNase ONE (Promega, Madison, WI) incubation times were 
determined by cleaving 0.5 µM RNA for 2, 5, and 10 minutes with 4.76x10-4 U/µl 
RNase in a 10 µl reaction mixture containing 300 mM KCl, 5 mM MgCl2, 20 mM 
HEPES, 5% DMSO, pH 7.5.  A mild alkaline hydrolysate was generated by 
incubating 0.5 µM RNA at 95 °C for 2, 5, and 10 min in *10 µl 50 mM Na2CO3, pH 
9.3.  The G-residue ladders were generated by digestion of 0.5 µM RNA for 2, 5, or 
10 minutes at 55 °C in 7 M Urea, 20 mM sodium citrate, 1 mM EDTA, pH 4.4 with 2 
U/µl RNase T1 (Promega, Madison, WI) in 10 µl. 
 
Enzymatic probing and electrophoresis 
Samples containing 0.5 µM of gel-purified, 5’end-labeled, and renatured RNA 
in 300 mM KCl, 5 mM MgCl2, 20 mM HEPES, 5% DMSO, pH 7.5 were incubated 
with PD173955N or adenosine ranging from 0 to 15 µM at 23 °C for 30 minutes in 5 
µl.  RNase ONE was added to the concentration of 4.76x10-4 U/µl and the samples 
were incubated for an additional 5 min at 37 °C.  All samples were brought to 47.5% 
formamide, 0.05% bromphenol blue, 0.05% xylene cyanol FF to stop cleavage.  The 
samples were resolved for 30-45 min at 2000V at 55 °C through 8% or 10% 
polyacrylamide gels containing 7 M urea gels in TBE buffer.  A partial alkaline 
hydrolysate of the RNA along with a G-residue ladder sample was run alongside a 
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series of footprinting analysis samples to aid in sequence identification. The dried 
gels were exposed to a Phosphor screen (GE Healthcare, Piscataway, NJ), which 
was read using the Typhoon 8600 Variable Model Imager (GE healthcare, 
Piscataway, NJ).  The gel images were analyzed using Semi-Automated 
Footprinting Analysis software (SAFA)  (Das, Laederach et al. 2005).   
 
Measurement of Binding Affinities by ITC  
See Chapter 2 (Materials and Methods) 
 
RESULTS AND DISCUSSION 
Preliminary RNA footprinting analysis was performed to determine the 
incubation time course of RNase degradation of the aptamer and the incubation time 
necessary to reach complete hydrolysis of RNA.  After 10 minutes of hydrolysis of 
the RNA complete degradation was observed (Figure 13, Page 58).  The G-residue 
ladder was obtained after incubating the RNA aptamer for 5 minutes with the RNase 
T1 which degrades single stranded RNA molecules at G residues.  When the RNA 
was digested with RNase T1 for longer than 5 min, the higher molecular weight RNA 
fragments were not visible on the gel (Figure 13, Page 58), and 2.5 minutes 
incubation with the RNase T1 was sufficient to create the G-ladder.  RNase ONE 
degrades single stranded RNAs to monomers and oligomers.  Longer incubation 
times then 5 minutes with the RNase ONE did not produce any additional RNA 
58 
 
fragments from digestion of the RNA, when compared to incubation times of less 
than 5 minutes (Figure 13, Page 58).  Based on this data all the enzymatic probing 
of the RNA aptamer with RNase ONE was done for 5 minutes using the conditions 
given in the Material and Methods (Chapter 3). 
 
 
Figure 13: Enzymatic probing of S570.R14.C32 RNA.  The gel image shows enzymatic 
probing of the S570.R14.C32 RNA.  The first three lanes represent hydrolysis of RNA at 2, 
5, and 10 minutes.  The next three lanes represent RNase T1 digestion of RNA at 2, 5, and 
10 minutes.  The last three lanes represent RNase ONE cleavage of the RNA at 2, 5, and 
10 minutes.  Secondary structure of RNA aptamer: the blue diamonds represent RNase T1 
digested nucleotides; the red colored letters represent RNase ONE digested nucleotides. 
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Structural analysis of the S570.R14C32RNA aptamer  
Prediction of the first truncated aptamer 
 The first attempt to truncate the S570.R14.C32 RNA involved using the M-fold 
software to predict possible secondary structures and comparing their stabilities.  
Because the random region of the selected aptamer was capable of forming a strong 
secondary structure (Figure 14c, Page 60), it was decided to chemically synthesize 
the random region of S570.R14.C10T1.  For the first truncation, the sequence was 
5’-GCUCAAUUUGUGAGUUUACUGUGCGAUUUCGAA-3’.  The extension T1 in the 
sequence name designates the first truncation tested.  The first truncation yielded an 
aptamer that had a very low affinity to PD173955N (Figure 14a, b, and c, Page 60).  
The results from this study led to the design of the second truncated aptamer.   
 
Prediction of the second truncated aptamer 
As mentioned previously M-fold predicted multiple secondary structures of the 
putative aptamer S570.R14C32RNA (Figure 8, Page 44).  Most predicted structures 
contained loops at both ends that were connected with a long stem.  RNase ONE 
footprinting analysis was performed to determine which predicted structure was 
likely to be correct.  Radioactive 5’-end labeled RNA was digested by the single 
stranded specific RNase ONE.  The RNA footprinting data was analyzed from gel 
images using SAFA, a program that uses a peak fitting routine to determine which 
regions of the nucleic acid are degraded more in the test sample compared to the 
 reference.  The extracted data were normalized such that the undige
corresponded to zero.   
 
Figure 14: ITC titration of PD173955N with S570.R14.C10T1RNA and the M
predicted Structure.  Shown is (a) a titration of 4 µM GK21 with 28 µM aptamer RNA after 
the data for the RNA aptamer dilution into buffer was 
titration into buffer. The KD
secondary structure of the RNA aptamer predicted by M
only once. 
60 
subtracted, (b) The RNA aptamer 
, calculated by the Origin software, is 57 mM, and (c) The 
-fold.  This experiment 
sted RNA 
 
-fold 
was done 
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When the putative aptamer was incubated with different concentrations of 
PD173955N for 30 minutes prior to digestion with RNase ONE, nucleotides 50-60 
were protected from RNase ONE cleavage at concentrations of 1 µM PD173955N 
and higher (Figure 15a, b, and c, Page 62).  The region of the RNA that was 
protected from RNase ONE cleavage is circled on the predicted secondary structure 
by M-fold, and that structure had the lowest ∆G of all predicted secondary structures 
(Figure 8, Page 44).  This result suggested that interaction of PD173955N with RNA 
protects the putative aptamer from RNase ONE digestion in the region of the 
predicted loop and that therefore PD173955N might bind within the loop region of 
the predicted RNA structure.  The same experiment was repeated with adenosine 
instead of PD173955N and protection from RNase ONE within the same region was 
not observed (Figure 16a, b, and c, Page 64).  This is consistent with the 
observation that adenosine does not bind the aptamer. 
 Based on the structural analysis just described, a truncated S570.R14.C32 
RNA aptamer named S570.R14.C32T2 was synthesized that contained the loop 
region and part of the long stem of the S570.R14.C32 RNA aptamer.  In order to 
stabilize the secondary structure four GC base pairs were added to the end of the 
stem.  Using M-fold, one of the predicted structures of the truncated aptamer was 
the same as for this region in the full length putative aptamer (Figure 17, Page 66).  
This truncation reduced the size of the putative aptamer from 74 to 37 nucleotides 
long.  The RNA sequence of S570.r14.c32T2 is: 5’-CGCGUUUACUGUGCGAUU 
 UCGAAUUCGACAGGACGCG
designates the second truncation.
Figure 15:  Enzymatic probing of S570.R14.C32 RNA
by incubating 0.5 µM of 5’ end labeled RNA aptamer with different concentrations of GK21, 
and probing it with RNase ONE in a 10 
a 10% PAGE denaturing urea gel.  A partial alkaline hyd
ladder) digest, and the undigested RNA aptamer were run to allow alignment with the kno
sequence for SAFA analysis.  (a) t
hydrolysate and the RNase T1 digest were remove
normalized such that the undigested RNA “equals” zero.  In this image the blue color 
regions show protection from RNase ONE digestion and the red color regions represent 
increased digestion.  b) one of the secondary structur
obtained and the region of interest is indicated by dotted lines.
experiment was repeated twice 
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.  Enzymatic probing was performed 
µl reaction mixture.  The cleaved RNAs were run on 
rolysate, RNase T1 (G residue 
he analyzed image using SAFA. The lanes that contained 
d from analysis.  The data were 
es that corresponds
  (c) the raw gel image
with similar results each time.    
 
wn 
 to the data 
. This 
 Figure 15:  (continued)  
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 Figure 16:  Enzymatic probing
(a) is the analyzed image using SAFA. 
T1 digest were removed from the analysis.  The data were normalized such that undigested 
RNA equals zero.  (b) one 
obtained.  The region of interest is indicated by dotted lines.
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 of S570.R14.C32 RNA pre-incubated with adenosine
 The lanes that contained hydrolysate and the RNase 
of the secondary structures that is consistent with the data 
  (c) the raw gel image
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 Figure 16:  (continued)
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The affinity of the S570.R14.C32T2 aptamer for PD173955N was determined 
by ITC in the buffer that mimics intracellular conditions (13.5 mM NaCl, 150 mM KCl, 
220 :M Na2HPO4, 440 :M KH2PO4, 100 µM MgSO4, 120 nM CaCl2, 120 µM MgCl2, 
20 mM HEPES, 5% DMSO, pH 7.25) and in selection buffer (0.3 M KCl, 5 mM 
MgCl2, 20 mM HEPES, 5% DMSO, pH 7.5).  The S570.R14.C32RNA and 
S570.R14.C32T2 were found to have similar affinities for PD173955N (Figure 18, 
Page 67; Table 2, Page 49). 
 
 
Figure 17:  RNA secondary structures predicted by M-fold.  Shown are the two most 
stable secondary structures of S570.R14.C32RNAT2 predicted by M-Fold.  
 
In summary, these results show that the S570.R14.C32 contains an aptamer 
that recognizes PD173955N with high affinity, and that the region of the RNA 
responsible for binding PD173955N resides in the region represented by 
 S570.R14.c32T2 RNA.  Thus, the portion of RNA that binds PD173955N was 
reduced from a 78mer to a 
 
Figure 18: Determination of the thermodynamic parameters of S570.R14.C32T2 RNA 
aptamer by ITC.  Shown is (a) the titr
containing 10 µM PD173955N after 
with PD173955N titrated into the buffer.  The K
This experiment was repeated 
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37mer.   
ation of 40 µM S570.R14.C32T2 RNA into a solution 
the reference data was subtracted, (b) reference data 
D, calculated by the Origin software
five times with similar results each time.    
 
, is 1 µM.  
 Figure 19: ITC titration of PD174265 with S570.R14.C32T2RNA
75 µM PD174265 with 5 µM S570.R14.C32T2RNA in 300mM KCl,  20
MgCl2, 5% DMSO pH 7.5 at 37
subtracted. The KD, calculated by the Origin software was
not show evidence of binding.  This experiment was repeated two times 
each time.    
 
CONCLUSION 
 The results presented her
might be making contact with PD173955N, because incubation of the
PD173955N protected it from RNase ONE cleavage.  Even though the use of RNase 
footprinting is time consuming, it can be used as an alternative method to determine 
binding affinities of the aptamers.   Also it has been shown that reducing the size of 
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with similar results 
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 is a titration of 
 aptamer with 
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the aptamer in combination with addition of four GC pairs did not decrease the 
affinity of the aptamer.  This means that, if necessary, other bases or even modified 
bases can be put on the end of the stem to make the selected aptamers more 
resistant to RNases in vitro.  Further an increase in specificity and affinity of the 
truncated S570.r14.c32T2 aptamer can be achieved by doping the loop region 
where it is believed that the aptamer makes contact with PD173955N.  Additional 
rounds of selection using the doped pool of aptamers would be necessary to do to 
get a more specific aptamer.  The doping process involves synthesis of a random 
pool in which each position of the selected aptamer is mutated by a certain 
percentage.  Doping would simplify the selection process and might give promising 
results.  The RNA aptamer already binds the PD173955N and by doping not as 
many selection rounds would be necessary to select a higher affinity aptamer, 
compared with starting the SELEX experiment from beginning.  
70 
 
CHAPTER 4: GENERAL DISSCUSION AND RECOMMENDATIONS FOR 
FUTURE RESEARCH 
 Aptamers are becoming a prominent tool in many research areas.  Their 
molecular properties make them more useful than antibodies for some applications.  
Development of the SELEX process made selection possible of rare nucleic acids to 
almost any target.  As presented in this thesis the selection procedure does not yield 
an aptamer every time.  The selection of aptamers is still very challenging, and 
needs more research to improve the efficiency of the selection procedure by finding 
methods to better capture RNA/target molecules.   The results presented suggest 
that the use of the mathematical simulation modeling is beneficial, and can guide the 
set up SELEX experiments’ starting conditions. 
In Chapter two, the S570.R14.C32 RNA aptamer was selected to 
PD173955N with a dissociation constant between 1-2 µM.  The same aptamer 
retained its binding affinity when it was used in buffer that mimics intracellular salt 
conditions.  After the size of aptamer was reduced to the binding region, the affinity 
was not changed as shown in Chapter III.  The high affinity toward PD173955N of 
the truncated aptamer may be because the nonbinding regions of the longer RNA 
interfered with aptamer folding in S570.R14.C32 RNA. 
 This aptamer was intended to be used to help increase the concentration of 
PD143955 inside cancerous leukemic cells.  The affinity of the selected aptamer to 
the target may need to be improved for the proposed model to work and this can be 
achieved by partially randomizing (doping) the selected aptamer and continuing 
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SELEX for a few more rounds.  This process is more promising than starting SELEX 
from the beginning.  From this it is possible to generate an aptamer with higher 
affinity and specificity for PD173955.   
 As shown in the thesis, determining the aptamers’ affinities was a very 
challenging task.  PD173955N and PD173955B are very insoluble compounds and 
for use in ITC, high concentrations of the compounds were needed.  The 
compounds were more soluble when DMSO was present in the binding reactions.  
The maximum solubility of PD173955N in selection buffer with 5% DMSO was 
35 µM.  It is unknown if 5% DMSO has any effect on the affinity of the RNA aptamer.  
Large concentrations of the RNA aptamers are needed for ITC experiments and they 
can be very costly.  New methods to determine the binding constants of aptamers 
for small molecules need to be explored.  ITC is a very reliable way to determine the 
binding constants, but for binding of low solubility small molecules is difficult to 
perform because it requires high concentrations of binding partners.  Attaching the 
insoluble compounds to something more soluble like streptavidin might be a better 
way to determine the binding constant via ITC.  Biotin labeled PD173955B can be 
attached to streptavidin and then concentrated down to get a highly concentrated 
sample that can be titrated into the cell compartment of the ITC machine containing 
the RNA aptamer.  This would help reduce the cost associated with a generation of 
large amounts of RNA. 
 There are a number of usages for the selected aptamer.  The selected 
aptamer can be attached to another aptamer like the PMSA aptamer, that 
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recognizes the PMSA protein present on the surface of prostate cancer cells, and be 
used to deliver PD173955N.  The use of an aptamer to deliver drugs has already 
been proven to work, where the PMSA aptamer in conjugation with a nanoparticle 
was used to deliver hydrophilic and hydrophobic chemotherapeutic drugs to prostate 
cancer cells.  The advantages of using aptamers over a nanoparticle are their 
smaller size that allows them to penetrate tissues faster.  Another advantage is that 
they are biological molecules, and therefore are degradable to precursors that are 
not damaging to the cells.  It would be ideal to take the S570.R14.C32 RNA 
aptamer, and create a 30% doped pool.  Use of 2’-F-pyrimidines would allow 
generation of a more RNase resistant aptamer.  The doped pool can be used to 
reselect again using PD173955B and substituting pyrimidines with 2’-F-pyrimidines.   
This selection would generate an aptamer that is more resistant to RNases and 
would increase its half life in blood. 
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